(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical Pricing Authority

New Delhi, 21st December, 2018

ORDER

S. O. 6253 In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

<u>Table</u>

Sl.	Name of the	Strength	Unit	Manufacturer &	Retail
No.	Formulation / Brand Name			Marketing Company	Price
(1)	(2)	(3)	(4)	(5)	(Rs.) (6)
1.	Telmisartan +	Each film coated bilayered tablet	1 Tablet	M/s Unison	3.21
1.	Amlodipine +	contains:	1 Tablet	Pharmaceuticals Pvt.	3.21
	Hydrochlorthaiazide	Telmisartan IP 40mg,		Ltd.	
	Tablets	Amlodipine Besylate IP eq. to		Ltd.	
	(Telmiride – AMH)	Amlodipine 5mg,			
	(Tellilliue - AMII)	Hydrochlorthaiazide IP 12.50mg			
		Tablets			
2.	Telmisartan +	Each uncoated bilayered tablet	1 Tablet	M/s Unison	3.13
۷.	Metoprolol Tablet	contains:	1 Tablet	Pharmaceuticals Pvt.	5.15
	(Telmiride – MT 25)	Telmisartan IP 40mg,		Ltd.	
	(Temminae 141 25)	Metoprolol Succinate IP 23.75mg,		Eta.	
		eq. to Metoprolol Tartrate IP 25mg			
		(as Extended Release)			
3.	Telmisartan +	Each uncoated bilayered tablet	1 Tablet	M/s Unison	3.57
	Metoprolol Tablet	contains:	1 145100	Pharmaceuticals Pvt.	0.07
	(Telmiride – MT 50)	Telmisartan IP 40mg,		Ltd.	
	(Metoprolol Succinate IP 47.50mg,			
		eq. to Metoprolol Tartrate IP 50mg			
		(as Extended Release)			
4.	Omeprazole +	Each hard gelatin capsule contains:	1 Capsule	M/s Unison	1.79
	Domperidone	Omeprazole 20mg (As enteric	1	Pharmaceuticals Pvt.	
	Capsule (OZSON-D)	coated pellets) +		Ltd.	
	1 ()	Domperidone IP 10mg (As coated			
		pellets) Capsule			
5.	(Diltra Tablets)	Each film coated tablet contains:	1 Tablet	M/s Aurobindo	114.06
	Lamivudine +	Lamivudine IP 300mg,		Pharma Limited	
	Tenofovir +	Tenofovir Disoproxil Fumarate IP			
	Dolugetravir Tablets	300mg			
		Dolugetravir Sodium eq. to			
		Dolutegravir 50mg			
6.	Metformin +	Each uncoated tablet contains:	1 Tablet	M/s Eris Lifesciences	9.04
	Pioglitazone Tablet	Metformin Hydrochloride IP		Ltd.	

		1000mg (in sustained release form), Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg			
7.	Clinidipine + Metoprolol Tablet	Each Film coated bilayered tablet contains: Clinidipine IP 10mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol tartrate 25mg (In prolonged release form)	1 Tablet	M/s Safetab Life Science / M/s Ajanta Pharma Limited	6.79
8.	Clinidipine + Metoprolol Tablet	Each Film coated bilayered tablet contains: Clinidipine IP 10mg, Metoprolol Succinate IP 47.50mg eq. to Metoprolol tartrate 50mg (In prolonged release form)	1 Tablet	M/s Safetab Life Science / M/s Ajanta Pharma Limited	8.19
9.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each Hard Gelatine Capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastation 20mg (As pellets) Aspirin IP 75mg (As enteric coated pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Micro Labs Limited	17.88
10.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each Hard Gelatine Capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastation 10mg (As pellets) Aspirin IP 75mg (As enteric coated pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd. / M/s Micro Labs Limited	11.46
11.	Escitalopram + Clonazepam Tablet (Recita LD)	Each film coated tablet contains: Escitalopram Oxalate eq. to Escitalopram 5mg, Clonazepam IP 0.25mg	1 Tablet	M/s IPCA Laboratories Ltd.	5.88
12.	Glimepiride + Pioglitazone Tablet	Each uncoated tablet contains: Glimepiride IP 1mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Lupin Limited	6.38
13.	Glimepiride + Pioglitazone Tablet	Each uncoated tablet contains: Glimepiride IP 2mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Lupin Limited	8.20
14.	Diclofenac + Serratiopeotidase Tablets (Diclotal S)	Each enteric coated Tablet Contains: Diclofenac Sodium IP 50mg, Serratiopeotidase IP 10mg eq. to 20000 enzyme activity units of Serratiopeptidase.	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd.	5.00
15.	Amoxycillin + Clavulanic Acid Suspension	Each combipack contains: (a) One bottle of Amoxycillin & Potassium Clavunate Oral Suspension L.P. Each 5ml of reconstituted	1 ml	M/s Malik Life Sciences Ltd. / M/s Wockhardt Limited	3.28

	T		Т	T	, ,
16.	Paracetamol + Phenylephrine + Caffeine + Diphenhydramine Tablet (NEMO-	suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400mg, Potassium Clavulante Diluted IP eq. to Clavulnic Acid 57mg (b) One vial of Sterile water for Injection IP Each vail contains: Sterile water for injection IP 30ml Each uncoated tablet contains: Paracetamol IP 500mg, Phenylephrine Hydrochloride IP 5mg, Caffeine (Anhydrous) IP 30mg,	1 Tablet	M/s Samson Laboratories Pvt. Ltd. / M/s Galpha Laboratories Limited	2.70
	KOLD-NF)	Diphenhydramine Hydrochloride IP 25mg			
17.	Daclatasvir + Sofosbuvir Tablet	Each film coated tablet contains: Daclatasvir Dihydrochloride eq. to Daclatasvir 60mg, Sofosbuvir 400mg	1 Tablet	M/s Natco Pharma Ltd. / M/s Aprazer Healthcare Pvt. Ltd.	556.442
18.	Choline Salicylate Solution + Benzalkonium Chloride Solution + Lignocaine Hydrochloride Gel (ULFREE Gel)	Choline Salicylate Solution B.P. eq. to Choline Salicylate 8.7% w/w, Benzalkonium Chloride Solution IP 0001% w/w, Lignocaine Hydrochloride IP 2.0% w/w	1 GM	M/s Group Pharmaceuticals Limited / M/s Hetero Healthcare Ltd.	4.29
19.	Bupivacaine + Fentanyl Injection	Each ml Contains: Bupivacaine Hydrochloride IP 1.00mg eq. to anyhydrous Bupivacaine Hydrochloride 0.948mg, Fentanyl Citrate IP eq. to Fentanyl 2.0mcg	20 ML Vial	M/s Troikaa Pharmaceuticals Ltd.	71.43
20.	Bupivacaine + Fentanyl Injection	Each ml Contains: Bupivacaine Hydrochloride IP 1.25mg eq. to anyhydrous Bupivacaine Hydrochloride 1.185mg, Fentanyl Citrate IP eq. to Fentanyl 2.0mcg	20 ML Vial	M/s Troikaa Pharmaceuticals Ltd.	75.89
21.	Diphtheria Toxoid + Tetanus Toxoid + Inactivated w-B. pertussis bulk + Hib (PRP- TT) (Hib PRP Conjugated with carrier protein Tetanus Toxoid) + Aluminium content (A13+) (as Aluminium Phosphate Gel) + Thiomersal 0.025mg, (Easy Four)	Each pack contains: Diphtheria Toxoid 20Lf (30 IU), Tetanus Toxoid 7.5Lf (60 IU), Inactivated w-B. pertussis bulk 10 IOU (4 IU), Hib (PRP- TT) (Hib PRP Conjugated with carrier protein Tetanus Toxoid) 10 ug, Aluminium content (A13+) (as Aluminium Phosphate Gel) 0.25mg, Thiomersal 0.025mg,	0.5 ML	M/s Panacea Biotech Ltd.	340.15

22.	Formoterol	Each 2ml Inhalation suspension	2 ML	M/s Akums Drugs &	36.04
	Fumarate +	contains:		Pharmaceuticals Ltd. /	
	Budesonide	Formoterol Fumarate Dihydrate IP		M/s Glenmark	
	Inhalation	eq. to Formoterol Fumarate 20mcg,		Pharmaceuticals	
	Suspension	Budesonide IP 0.5mg in an Isotonic		Limited	
	(Smartules)	Solution			
23.	Formoterol	Each 2ml Inhalation suspension	2 ML	M/s Akums Drugs &	42.12
	Fumarate +	contains:		Pharmaceuticals Ltd. /	
	Budesonide	Formoterol Fumarate Dihydrate IP		M/s Glenmark	
	Inhalation	eq. to Formoterol Fumarate 20mcg,		Pharmaceuticals	
	Suspension	Budesonide IP 1.0mg in an Isotonic		Limited	
	(Smartules)	Solution			

Note:

- (a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/193/61/2018/F

F. No. 8(61)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director